Merck Q3 revenue $16.0B (+7%), KEYTRUDA up 17%; cuts FY EPS guidance on $5.5B Daiichi Sankyo charge

Merck & Co., Inc.

2023-Q3 EPS reported $0.62 revenue$45,485,000,000

Q3 total sales $16.0B (+7% YoY); GAAP EPS $1.86, Non-GAAP EPS $2.13 (+15% YoY).
KEYTRUDA sales $6.3B (+17%); GARDASIL/GARDASIL 9 sales $2.6B (+13%).
Full-year 2023 sales guidance raised to $59.7-$60.2B; Non-GAAP EPS guidance lowered to $1.33-$1.38 due to $5.5B upfront charge from Daiichi Sankyo collaboration.
Entered collaboration with Daiichi Sankyo for three clinical-stage ADC candidates; upfront payment $5.5B.
FDA approved KEYTRUDA for perioperative NSCLC; priority review for sotatercept (PDUFA March 26, 2024).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Merck & Co., Inc. updated its the third quarter of 2023 guidance (raised).

Period: the third quarter of 2023
Guidance: raised
Result: reported results

Exact text from the filing

Incorporated by reference is a press release issued by Merck & Co., Inc. on October 26, 2023, regarding earnings for the third quarter of 2023, attached as Exhibit 99.1.

View on SEC.gov

Browse all earnings releases →

Merck & Co., Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-111585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.